Compare · ASBP vs JNJ
ASBP vs JNJ
Side-by-side comparison of Aspire Biopharma Holdings Inc. (ASBP) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ASBP and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $542.44B, about 440683.9x ASBP ($1.2M).
- Over the past year, ASBP is down 98.7% and JNJ is up 45.1% - JNJ leads by 143.8 points.
- JNJ has been more active in the news (26 items in the past 4 weeks vs 14 for ASBP).
- JNJ has more recent analyst coverage (25 ratings vs 0 for ASBP).
- Company
- Aspire Biopharma Holdings Inc.
- Johnson & Johnson
- Price
- $0.24+19.94%
- $225.28-0.96%
- Market cap
- $1.2M
- $542.44B
- 1M return
- -77.14%
- -5.87%
- 1Y return
- -98.69%
- +45.08%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 14
- 26
- Recent ratings
- 0
- 25
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest ASBP
- Aspire Biopharma Announces $5.0 Million Share Repurchase Program
- Aspire Biopharma Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition
- Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo
- Amendment: Aspire Biopharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Aspire Biopharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Aspire Biopharma Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Aspire Biopharma Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue
- Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion
Latest JNJ
- SEC Form 4 filed by Director Woods Eugene A.
- SEC Form 4 filed by Director West Nadja
- SEC Form 4 filed by Director Weinberger Mark A
- SEC Form 4 filed by Director Pinto Daniel E
- SEC Form 4 filed by Director Morikis John G
- SEC Form 4 filed by Director Mcclellan Mark B.
- SEC Form 4 filed by Director Joly Hubert
- SEC Form 4 filed by Director Johnson Paula A
- SEC Form 4 filed by Director Hewson Marillyn A
- SEC Form 4 filed by Director Doudna Jennifer A